Search

Now showing items 1-2 of 2

DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo.

Li, J-L; Sainson, RCA; Oon, CE; Turley, H; Leek, R; Sheldon, H; Bridges, E; Shi, W; Snell, C; Bowden, ET; Wu, H; Chowdhury, PS; Russell, AJ; Montgomery, CP; Poulsom, R; Harris, AL (2011-09-15)

Resistance to VEGF inhibitors is emerging as a major clinical problem. Notch signaling has been implicated in tumor angiogenesis. Therefore, to investigate mechanisms of resistance to angiogenesis inhibitors, we transduced ...

ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer.

Feldinger, K; Generali, D; Kramer-Marek, G; Gijsen, M; Ng, TB; Wong, JH; Strina, C; Cappelletti, M; Andreis, D; Li, J-L; Bridges, E; Turley, H; Leek, R; Roxanis, I; Capala, J; Murphy, G; Harris, AL; Kong, A (2014-08-30)

Trastuzumab prolongs survival in HER2 positive breast cancer patients. However, resistance remains a challenge. We have previously shown that ADAM17 plays a key role in maintaining HER2 phosphorylation during trastuzumab ...